Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab Vedotin”

186 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 186 results

Not applicableStudy completedNCT01868451
What this trial is testing

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center 118
Testing effectiveness (Phase 2)Study completedNCT02227199
What this trial is testing

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
University of Washington 45
Large-scale testing (Phase 3)Study completedNCT01578499
What this trial is testing

Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Who this might be right for
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
Millennium Pharmaceuticals, Inc. 131
Testing effectiveness (Phase 2)Active Not RecruitingNCT03113500
What this trial is testing

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Who this might be right for
Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell Lymphoma, ALK-NegativeAnaplastic Large Cell Lymphoma, ALK-Positive+8 more
City of Hope Medical Center 48
Not applicableStudy completedNCT01578967
What this trial is testing

Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma, Adult
UNC Lineberger Comprehensive Cancer Center 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT03233347
What this trial is testing

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Who this might be right for
Ann Arbor Stage I Hodgkin LymphomaAnn Arbor Stage IA Hodgkin LymphomaAnn Arbor Stage IB Hodgkin Lymphoma+4 more
Academic and Community Cancer Research United 82
Testing effectiveness (Phase 2)Active Not RecruitingNCT02734771
What this trial is testing

Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-Cell Lymphoma
Patrick Reagan 24
Early research (Phase 1)Study completedNCT01830777
What this trial is testing

Brentuximab Vedotin + Re-induction Chemotherapy for AML

Who this might be right for
Acute Myelogenous Leukemia
Massachusetts General Hospital 22
Testing effectiveness (Phase 2)UnknownNCT05006664
What this trial is testing

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Who this might be right for
Lymphoma, T-Cell, Peripheral
Czech Lymphoma Study Group 33
Testing effectiveness (Phase 2)Study completedNCT00848926
What this trial is testing

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Who this might be right for
Disease, Hodgkin
Seagen Inc. 102
Testing effectiveness (Phase 2)Study completedNCT01874054
What this trial is testing

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Who this might be right for
Hodgkin Disease
Seagen Inc. 55
Testing effectiveness (Phase 2)Looking for participantsNCT03587844
What this trial is testing

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Who this might be right for
Mycosis FungoidesLymphomatoid PapulosisSezary Syndrome
Memorial Sloan Kettering Cancer Center 58
Not applicableStudy completedNCT06857500
What this trial is testing

Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience

Who this might be right for
Classic Hodgkin LymphomaAdvanced Hodgkin Lymphoma
Federico II University 200
Testing effectiveness (Phase 2)Study completedNCT01851200
What this trial is testing

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Who this might be right for
Germ Cell Cancer
Fondazione Michelangelo 9
Not applicableStudy completedNCT03729609
What this trial is testing

Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Untreated CD30-Positive Hodgkin's Lymphoma"

Who this might be right for
Untreated CD30-Positive Hodgkin's Lymphoma
Takeda 113
Post-approval studies (Phase 4)Not Yet RecruitingNCT06761911
What this trial is testing

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma (Category)
Xiuhua Sun 100
Early research (Phase 1)Study completedNCT00430846
What this trial is testing

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

Who this might be right for
Lymphoma, Non-HodgkinDisease, HodgkinLymphoma, Large-Cell, Anaplastic
Seagen Inc. 45
Early research (Phase 1)Study completedNCT02616965
What this trial is testing

Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma

Who this might be right for
Cutaneous T-cell Lymphoma (CTCL)
Fox Chase Cancer Center 16
Testing effectiveness (Phase 2)Study completedNCT01979536
What this trial is testing

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveAnn Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell LymphomaAnn Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma+1 more
National Cancer Institute (NCI) 137
Early research (Phase 1)WithdrawnNCT02780011
What this trial is testing

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

Who this might be right for
CD30-positive LymphomaCD30-positive Solid Tumor
Eric Bernicker, MD
Load More Results